<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755494</url>
  </required_header>
  <id_info>
    <org_study_id>D1681C00001</org_study_id>
    <nct_id>NCT01755494</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration</brief_title>
  <acronym>SAXA</acronym>
  <official_title>A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacokinetic parameters of
      saxagliptin and metformin in healthy male Chinese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the
      Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the
      Individual Components in two cohorts of Healthy Chinese Subjects under Fed Conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for saxagliptin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve (AUC) for saxagliptin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve (AUC) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for 5-hydroxy saxagliptin</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration time curve (AUC) for 5-hydroxy saxagliptin</measure>
    <time_frame>Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessment based on medical review of AE reports:physical examination, ECG, heart rate, blood pressure, lab test</measure>
    <time_frame>Study duration for individual subject (up to 34 days) when the safety data are collected</time_frame>
    <description>Assessment for 5 mg saxagliptin co-administered with up to 1000 mg metformin XR given either separately, or as a single FDC tablet.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Type 2 Diabetes Mellitus(T2DM)</condition>
  <arm_group>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5 mg</intervention_name>
    <description>Saxagliptin oral tablet 5mg, single dose</description>
    <arm_group_label>Lower dose</arm_group_label>
    <arm_group_label>Higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR 500 mg</intervention_name>
    <description>Metformin XR oral tablet 500 mg, single dose</description>
    <arm_group_label>Lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mertformin XR 2 x 500 mg</intervention_name>
    <description>Metformin XR oral tablet 2 x 500 mg, single dose</description>
    <arm_group_label>Higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Komboglyze XR 5/500 mg</intervention_name>
    <description>oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose</description>
    <arm_group_label>Lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Komboglyze XR 5/1000 mg</intervention_name>
    <description>oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose</description>
    <arm_group_label>Higher dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese ethnicity which is defined as having both parents and 4 grandparents who are
             Chinese

          -  Healthy male subjects as determined by no clinically significant deviation from normal
             in medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Men, ages 18 to 40 years, inclusive. The age difference among the subjects is within
             10 years

          -  Weigh at least 50 kg and have a body mass index (BMI) between 19 and 24 kg/m2

          -  Sexually active fertile men must use effective birth control throughout the study and
             for up to 90 days after the last dose of investigational product if their partners are
             women of child bearing potential

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent gastrointestinal disease

          -  Subjects that have lymphocytopenia or thrombocytopenia

          -  History of autoimmune skin disorder

          -  Estimatedcreatinine clearance of less than 80 mL/min
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boaz Hirshberg</last_name>
    <role>Study Director</role>
    <affiliation>Room No.: C3C-718, 1800 Concord Pike, PO Box 15437, Wilmington DE 19850-5437, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiyan Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital (PU3), 49 North Garden Road, Haidian District, Beijing 100191, PR. China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1189&amp;filename=D1681C00001.pdf</url>
    <description>D1681C00001.pdf</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes, Saxagliptin, Metformin,Fixed dose combination tablet, Bioequivalence, pharmacokinetic, safety, tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

